Exendin-4 effects on islet volume and number in the mouse pancreas

Bratislava Medical Journal

Volumn 115, Issue 8, 2014, Pages 502-507

  Khorsandi, L ^a   Nejad Dehbashi, F ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Exendin 4; Islet hypertrophy; Mice; Pancreas; Stereology

Indexed keywords

EID: 84906957863     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: 10.4149/BLL_2014_098     Document Type: Article

References (35)

1. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both b-Cell replication and neogenesis, resulting in increased b-Cell mass and improved glucose tolerance in diabetic rats. Diabetologia 1999; 48 (12): 2270-2276.
2. Hui R, Wright C, Perfetti R. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1 positive pancreatic ductal cells into insulin-secretion cells. Diabetes 2001; 50 (4): 785-796.
3. Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin producing cells. Endocrinology 2002; 143 (8): 3152-3161.
4. Hardikar AA, Wang XY, William L, Kwok J, Wong R, Tuch BE. Functional maturation of fetal porcine beta cells by glucagon-like peptide 1 and cholecystokinin. Endocrinology 2002; 143 (9): 3505-3514.
5. Kieffer TJ, Mcintosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide-1 in vitro and invivo by dipeptidyl peptidase IV. Endocrinology 1995; 136 (8): 3585-3596.
6. Zhou J, Wang Y, Pineyro MA, Egan JM. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulinproducing cells. Diabetes 1999; 48 (12): 2358-2366.
7. Stoffers, DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habner JF, Egan JM. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2004; 49 (5): 741-748.
8. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003; 27 (3): 313-318.
9. De Fronzo RA, Ranter RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28 (5): 1092-1100.
10. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27 (11): 2628-2635.
11. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman, MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28 (5): 1083-1091.
12. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8 (4): 436-447
13. Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes. Clin Ther 2007; 29 (1): 139-153.
14. Perry T, Haughey NJ, Mattson MP, Egan JM, Grieg NH. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 2000a; 302 (3): 881-888.
15. Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002b; 300 (3): 958-966.
16. During MJ, Cao L, Zuzga DS, Francis JS, Fitzimons HL, Jiao X. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003; 9 (9): 1173-1179.
17. Vella A, Shan P, Reed AS, Adkins AS, Basu R, Rizza RA. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia 2002; 45 (10): 1410-1415.
18. Ranta F, Ayram D, Berchtold S, Adkins AS, Basu R, Rizza RA. Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4. Diabetes 2006; 55 (5): 1380-1390.
19. Chen YH, Wang JH, Li ZQ, Yi ZH. Effects of exendin-4 on rat cardiomyocyte apoptosis early after severe scald injury. Nan. Fang. Yi Ke Da Xue Xue Bao 2011; 31 (6): 1101-1104.
20. Nachnani JS, Bulchandani DG, Nookala A, Herndon B, Molteni A. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010; 53 (1): 153-159.
21. Briyal S, Gulati K, Gulati A. Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats. Brain Res 2012; 1427: 23-34.
22. Gundersen HJ, Jensen EB. The efficiency of systematic sampling in stereology and its prediction. J Microsc 1987; 147 (3): 229-263.
23. Bock T, Pakkenberg B, Buschard K. Inctrased islet volume but unchanged islet number in ob/ob mice. Diabetes 2003; 52 (7): 1716-1722.
24. Nyengaard JR. Stereologic methods and their application in kidney research. J Am Soc Nephrol 1999; 10 (5): 1100-1123.
25. Sun Y, Zhang L, Gu HF, Han W, Ren M, Wang F, et al. Peroxisome proliferator-activated receptor-1 regulates the expression of pancreatic/ duodenal homeobox-1 in rat Insulinoma (INS-1) cells and ameliorates glucose-induced insulin secretion impaired by palmitate. Endocrinology 2007; 149 (2): 662-671.
26. Edwel A, Lindstrom P, Edvell A. Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?). Endocrinology 1999; 140 (2): 778-783.
27. Perfetty R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucoseintolerant rats. Endocrinology 2000; 141 (12): 4600-4605.
28. Tourrel C, Bailbe D, Lacome M, Meile MJ, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 2002; 51 (5): 1443-1452.
29. Tourrel C, Bailbe, D, Meile MJ, Kergoat M, Portha B. Glucagon-like peptide-1 and exendin-4 stimulate beta cell neogenesis in streptozotocintreated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001; 50 (7): 1562-1570.
30. Park S, Hong SM, Sung SR. Exendin-4 and exercise promotes betacell function and mass through IRS2 induction in islets of diabetic rats. Life Sci 2008; 82 (9-10): 503-511.
31. Fan R, Kang Z, He L, Chan J, Xu G. Exendin-4 improves blood glucose control in both young and aging normal non-diabetic mice, possible contribution of beta cell independent effects. PlOS One 2011; 6 (5): e20443.
32. Olson AL, Pessin JE. Structure function, and regulation of the mammalian facilitative glucose transporter gene family. Annu Rev Nutr 1993; 16: 235-256.
33. Lopes Da Costa C, Sampaio De Freitas M, Sanches Moura A. Insulin secretion and GLUT-2 expression in undernourished neonate rats. J Nutr Biochem 2004; 15 (4): 236-241.
34. Verspohl EJ. Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase- 4 inhibitors. Pharmacol Ther 2009; 124 (1): 113-138.
35. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H et al. Glucagon-like peptide1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144 (12): 5149-5158.